"3"^^ . . "531362" . . "RIV/00216224:14110/05:00014065!RIV10-MSM-14110___" . . "Je shrnut v\u00FDznam antidepresivn\u011B p\u016Fsob\u00EDc\u00EDch l\u00E1tek pro dal\u0161\u00ED rozvoj oboru. D\u00E1le jsou detailn\u011Bji prob\u00EDr\u00E1ny dv\u011B skupiny nov\u011Bj\u0161\u00EDch antidepresiv - specifick\u00E1 antidepresiva ovliv\u0148uj\u00EDc\u00ED preferen\u010Dn\u011B serotonin nebo noradrenalin/dopamin a du\u00E1ln\u00ED antidepresiva. Jsou uv\u00E1d\u011Bny indika\u010Dn\u00ED mo\u017Enosti u depresivn\u00ED poruchy - c\u00EDlen\u00E1 l\u00E9\u010Dba deprese dle p\u0159eva\u017Euj\u00EDc\u00EDch symptom\u016F, rezidu\u00E1ln\u00ED symptomatologie, prolomen\u00ED farmakorezistence. Vzhledem k tomu, \u017Ee specifick\u00E1 antidepresiva jsou dob\u0159e sn\u00E1\u0161ena a jsou bezpe\u010Dn\u00E1, roz\u0161i\u0159uj\u00ED se jejich indikace i mimo depresivn\u00ED poruchu."@cs . "RIV/00216224:14110/05:00014065" . . . "6." . . . "1"^^ . "CZ - \u010Cesk\u00E1 republika" . "Pharmacotherapeutic options in depression"@en . "1"^^ . "\u010Ce\u0161kov\u00E1, Eva" . "Pharmacotherapeutic options in depression"@en . "specific antidepressants; dual acting antidepressants; target symptoms; residual symptoms; breaktrough of pharmacoresistance; indication"@en . "Psychiatrie pro praxi" . . . . "The importance of antidepressants for the further development of psychiatry is summarized. In more details 2 groups of antidepressants, e.g. specific antidepressant influencing preferentially serotonin or norepinephrine/dopamine and dual antidepressants are discussed. New indication within depressive disorder - targeted treatment of depression according to prevalence of symptoms, residual symptoms and breaktrough of pharmacoresistance are discussed. Because the specific antidepressants are well tolerated and safe, the indications are widened also outside the range of depressive disorders."@en . . . "Mo\u017Enosti farmakoterapie deprese"@cs . "Je shrnut v\u00FDznam antidepresivn\u011B p\u016Fsob\u00EDc\u00EDch l\u00E1tek pro dal\u0161\u00ED rozvoj oboru. D\u00E1le jsou detailn\u011Bji prob\u00EDr\u00E1ny dv\u011B skupiny nov\u011Bj\u0161\u00EDch antidepresiv - specifick\u00E1 antidepresiva ovliv\u0148uj\u00EDc\u00ED preferen\u010Dn\u011B serotonin nebo noradrenalin/dopamin a du\u00E1ln\u00ED antidepresiva. Jsou uv\u00E1d\u011Bny indika\u010Dn\u00ED mo\u017Enosti u depresivn\u00ED poruchy - c\u00EDlen\u00E1 l\u00E9\u010Dba deprese dle p\u0159eva\u017Euj\u00EDc\u00EDch symptom\u016F, rezidu\u00E1ln\u00ED symptomatologie, prolomen\u00ED farmakorezistence. Vzhledem k tomu, \u017Ee specifick\u00E1 antidepresiva jsou dob\u0159e sn\u00E1\u0161ena a jsou bezpe\u010Dn\u00E1, roz\u0161i\u0159uj\u00ED se jejich indikace i mimo depresivn\u00ED poruchu." . "Mo\u017Enosti farmakoterapie deprese" . . "Mo\u017Enosti farmakoterapie deprese"@cs . "1213-0508" . . "Z(MSM0021622404)" . "[6D92A088BE4D]" . . "5" . "Mo\u017Enosti farmakoterapie deprese" . . . "14110" . .